Heart Failure’s Near Dead and Dying Reconsidering Our Heart Transplant Wait List Scheme⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Young, James B.
H
N
R
T
J
C
U
n
f
v
c
r
c
5
S
“
J
s
b
h
D
h
o
r
f
W
r
b
d
w
d
H
m
e
a
g
h
t
w
m
o
t
n
t
h
f
d
i
a
i
c
o
a
L
p
(
i
a
p
a
d
f
d
c
s
f
U
a
a
m
o
t
d
M
s
e
*
v
A
o
Journal of the American College of Cardiology Vol. 50, No. 13, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.008EDITORIAL COMMENT
eart Failure’s
ear Dead and Dying
econsidering Our Heart
ransplant Wait List Scheme*
ames B. Young, MD, FACC
leveland, Ohio
Louis Washkansky had been admitted to Groote Schuur on Sep-
tember 14, 1967. . . six weeks later he lay breathless and dying, in
ward A1, his blue and bloated body barely sustained by a heart
reduced to a third of its pumping capacity. . . he slid away into a
diabetic coma in late October. . . he had also swelled to twice his
normal size with edema and. . . had put on thirty-five pounds in
four days. Washkansky had to be propped in a chair so that, after
drilling holes in his legs, they could drain the excess fluid. His eyes
had become like slits in a grotesquely bloated face (1).
In later studies we found that the mean survival time of
patients who were accepted for cardiac transplantation, but
died while awaiting a donor, was 27 days (2).
nlike the situation with Mr. Washkansky, Professor Bar-
ard’s first heart transplant patient, a diagnosis of heart
ailure is not necessarily a death sentence. There is great
ariability in the prognosis of these patients (3). The
hallenge is to determine which patients might require more
adical measures, such as heart transplantation, to make a
linical difference. Much has been learned during the past
0 years. It was in October 1967 that Braunwald, Ross, and
onnenblick ushered in the “modern” era of heart failure
thinking” with a seminal review in the New England
ournal of Medicine that was an unparalleled 5-part, 50-page
eries that contained 30 now-classic figures (4). Furosemide
See page 1282
ecame available that year, and the first “successful” human
eart transplant was performed by Dr. Christian Barnard on
ecember 3, 1967. Great, although still inadequate, insight
as subsequently emerged characterizing the pathophysiol-
gy of heart failure and best treatments (3). Today, we must
econsider our approach to the severely ill patient considered
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Division of Medicine, Kaufman Center for Heart Failure, Lerner College
f Medicine of Case Western Reserve University, Cleveland, Ohio.or heart transplant. The clinical picture painted by Mr.
ashkansky was a dismal one. And, importantly, one must
emember that the treatment options in 1967 were limited,
asically, to digitalis glycoside therapy and rudimentary
econgestion methods. Indeed, Washkansky was treated
ith lymphatic drainage tubes which, perhaps, lead to his
emise from pseudomonas sepsis caused by leg cellulitis.
eart transplant was a desperate and radical option for this
ortally ill patient, but the boutique operation has today
merged as a treatment choice for select patients with very
dvanced disease. Who should belong to that exclusive
roup? As noted already by Cooper et al. (2), early in the
eart transplant experience, patients waiting were an ex-
raordinarily ill lot, surviving only weeks if a donor organ
as not found. That has changed.
Since Washkansky in 1967, major breakthroughs in
anagement of heart failure have included introduction
f inhibitors of the renin-angiotensin-aldosterone sys-
em, beta-adrenergic blocking agents, new diuretics,
ontransplant surgical therapies, cardiac resynchroniza-
ion, and implantable defibrillating devices. These tools
ave dramatically changed the manner in which we care
or our patients. Furthermore, Barnard had no guidelines
etailing best management practices, but we have many,
ncluding guidelines for heart transplant patient selection
nd strict rules for cardiac donor allocation (5,6). There
s a problem, however, as patient selection schemes are
ontroversial and the manner in which we dole out donor
rgans may not result it the best utilization of this scarce
nd lifesaving resource (6 –9).
Tackling this issue is the artful and elegant analysis by
ietz and Miller (9) of the Organ Procurement and Trans-
lantation Network/United Network of Organ Sharing
OPTN/UNOS) database between 1990 and 2005 in this
ssue of the Journal. The analysis compared survival in
lmost 50,000 UNOS registrants waiting for heart trans-
lant in 3 distinct time periods: 1990 to 1994, 1995 to 1999,
nd 2000 to 2005 (eras I to III). Because the OPTN/UNOS
onor organ allocation scheme is driven in a formulaic
ashion according to severity of illness, distance from the
onor to patient, and time in the queue, it is possible to
ompare outcomes during the waiting periods, particularly
urvival, in a spectrum of patients. During these eras, heart
ailure severity was characterized by patient assignation to
NOS status 1 or 2 categories. A status 1 patient is most ill
nd is generally hospitalized and supported with aggressive
nd risky therapies, including chronic inotrope infusion or
echanical circulatory support. Status 2 patients are all
thers awaiting organ allocation and are predominantly in
he outpatient setting. The UNOS has a very explicit
efinition of these categories. The analysis by Lietz and
iller (9) demonstrated substantial improvement in 1-year
urvival on the waiting list, from 49.5% to 68.9% between
ras I and III. Important was the improvement in 1-year
urvival in status 2 patients, with deaths decreasing from
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Editorial Comment September 25, 2007:1291–32.5% to 7.5% during the same period. This improvement
n survival was not related to heart transplantation, as the
ikelihood of this happening was no different across the eras.
o identify morbidity risk, a multivariable Cox proportional
azards model using stepwise logistic selection of important
arameters indicated that age 60 years, Caucasian race,
eight 70 kg, pulmonary capillary wedge pressure 20
m Hg, serum creatinine 1.5 mg/dl, continuous inotrope
nfusion, use of intra-aortic balloon pump, mechanical
irculatory device support, need for mechanical ventilation,
iagnosis of restrictive or valvular cardiomyopathy, previous
ardiac allograft failure, and the absence of an implantable
ardioverter-defibrillator (ICD)-predicted death. Perhaps
n important message from this analysis is that we can likely
ave even more lives with aggressive yet appropriate use of
CD implantation (and perhaps cardiac resynchronization
herapy, which was not addressed) (3). Indeed, the propor-
ion of patients with ICDs increased from 18.3% in era II to
6.7% in era III.
Lietz and Miller (9) concluded that survival of patients on
he heart transplant wait list has improved significantly since
990. Furthermore, the survival difference of status 1 versus
cohorts suggests that it is the status 1 patient who depends
n cardiac transplantation for survival much more than
hose listed as status 2. By clarifying risk factors for early
ait list mortality, a change in the heart transplant organ
llocation scheme might be effected. Indeed, altering the
llocation process to take into account the identified risk
actors for early mortality on the wait list seems rational, as
oes redefining who should be listed for heart transplant in
he first place. Related to this was the observation that
-year survival of patients listed as status 2 (81.4%) ap-
roaches that of patients after heart transplantation.
The strengths of the Lietz and Miller (9) work lie in the
nalysis sophistication, number of subjects, and complete-
ess of data. The OPTN requires every patient waiting to be
isted in the UNOS registry, with vital status accurately
etermined at regular intervals. Thus, a complete overview
f this special group is possible. Although some patients
oved between status 1 and 2, and a proportion were
emoved from the waiting list during the fiduciary periods,
hese numbers were small in contrast with the overall
ohort.
Because donor hearts for cardiac transplantation are
carce and success of the procedure now great, debate about
rgan allocation has been long and heated. The specter of
nethical donor organ procurement is also driven by this
upply/demand inequity. The concept of “net benefit,” both
ith respect to those on the waiting lists and patients
eceiving donor organs is essential to the debate. How do we
est use this scarce therapeutic and often life-saving dona-
ion? Unfortunately, recent debate at the International
ociety for Heart and Lung Transplantation Scientific
essions (San Francisco, April, 2007) did not resolve thisssue (7). One problem is that cardiac transplantationWashkansky’s case included) has never been put to the test
f a randomized clinical trial. That is understandable. The
rocedure clearly reverses much heart failure pathophysiol-
gy, attenuates symptoms, improves exercise, allows better
uality of life, and prolongs survival in appropriately selected
ear dead and dying patients, despite the morbidity of the
peration and immunosuppressives and the limitation of a
enervated allograft. Because of these issues survival benefit
s not clearly the case in less ill heart failure patients
haracterized as UNOS status 2, although they may feel
etter.
Looking at much of the same OPTN/UNOS data in a
lightly different manner, the overall death rate on the
aiting list per 1,000 patient-years at risk was 432 in 1990
ersus 172 in 1999. The UNOS status 1A patients (the
ost ill of the status 1 category) had a death rate of 582 per
,000 patient-years at risk versus 131 in the status 2 cohort.
sing these data one notes that between 1996 and 1998,
n  11,542) for every 12 UNOS status 1 patients waiting
month for organ allocation, 1 died compared with 1 death
or every 120 status 2 patients (6).
Given the insightful and provocative information pre-
ented by Lietz and Miller (9), is it not time that the benefit
f cardiac transplantation in stable outpatients with chronic
eart failure (UNOS status 2) be tested in a randomized
rial? Clearly, heart transplantion was introduced into clin-
cal practice as a “breakthrough” therapy in patients near
eath without randomized clinical trial evaluation. Recent
mproved outcomes with medical and surgical heart failure
herapies have reduced the comparative benefit gained with
eart transplant in some populations. Data suggest that
atients at the greatest risk of death (UNOS status 1)
enefit from transplant, whereas low-risk cohorts (status 2)
ight not. We must then design a properly controlled
linical trial that could have as a primary end point the
omposite of time to death or transplantation as a UNOS
tatus 1 patient. Secondary end points could explore impor-
ant quality of life and symptom relief issues. This certainly
s not the first time such a trial has been proposed (8). Until
his important issue has been resolved, perhaps we should
et back to transplanting more patients like Mr. Washkan-
ky. Outcomes in these individuals are now excellent and
net benefit” much more intuitive.
eprint request and correspondence: Dr. James B. Young,
ivision of Medicine, Cleveland Clinic Foundation, 9500 Euclid
venue T-13, Cleveland, Ohio 44195. E-mail: youngj@ccf.org.
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